Anti-CD30 antibody-based therapy.
Curr Opin Oncol
; 12(6): 588-93, 2000 Nov.
Article
em En
| MEDLINE
| ID: mdl-11085459
ABSTRACT
The increased expression of CD30 on some neoplasms versus its limited expression on normal tissue makes it an excellent target for antibody-based therapy. Recent studies have shown that anti-CD30 antibodies may serve as signaling molecules as well as mediators of interactions with the immune system. Unmodified anti-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examined in preclinical and clinical studies. The data show that anti-CD30-based therapies are promising new treatment modalities for CD30+ neoplasms.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antígeno Ki-1
/
Anticorpos
/
Neoplasias
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Curr Opin Oncol
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Estados Unidos